Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

RusHydro became the sole owner of Green Crab carsharing

7/3/23 HYDR

Yandex.Delivery will enter the Kyrgyz market by the end of the year

7/3/23 YNDX

CarMoney completed the sale of additional shares

7/3/23 CARM

Novatek tripled its investment in R&D

7/3/23 NVTK

Shareholders of Novorossiysk Bakery Products Plant approved dividends for 2022

7/3/23 NKHP

VKontakte CEO and CTO will leave the company

7/3/23 VKCO

VK acquires 26% of application developer Nota-RTK LLC

7/3/23 VKCO

Samolet will build three mixed-use complexes in New Moscow

7/3/23 SMLT

Tesla sales in Q2 up 83%

7/3/23 TSLA

CarMoney to sell 110.7 million more shares

7/3/23 CARM